Related Experiment Video
Updated: Aug 10, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Medically Refractory Lymphocytic Colitis Successfully Treated With Upadacitinib.
Yusuke Miyatani1, David Choi1, Xiaotang Du2
1Department of Medicine, Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL.
ACG Case Reports Journal
|February 15, 2023
Summary
Lymphocytic colitis refractory to standard treatments responded well to upadacitinib. This Janus kinase 1 inhibitor offers a new option for difficult microscopic colitis cases.
Area of Science:
- Gastroenterology and immunology
- Investigational therapies for inflammatory bowel disease
Background:
- Lymphocytic colitis is a microscopic colitis with normal-appearing mucosa and intraepithelial lymphocytosis.
- Refractory microscopic colitis poses a therapeutic challenge with limited evidence for novel treatments.
Observation:
- A case of lymphocytic colitis resistant to conventional and immunosuppressive therapies was identified.
- The patient's condition did not improve with standard treatment protocols.
Findings:
- Upadacitinib, a selective Janus kinase 1 inhibitor, demonstrated prompt efficacy.
- This represents the first reported instance of upadacitinib successfully treating refractory lymphocytic colitis.
Implications:
- Upadacitinib may offer a promising therapeutic avenue for patients with refractory lymphocytic colitis.
- Further research is warranted to explore the role of JAK inhibitors in managing microscopic colitis.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
209
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
209
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
226
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
226
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
01:21Drugs for Treatment of Constipation-Predominant IBS
266
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
266
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204